{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 49,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_messages",
  "function": "quantify_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/19",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 1,
        "x": 0,
        "y": 0.83
      },
      "kind": "callout",
      "text": "Ultomiris potential to be first-and-only medicine for HSCT-TMA, and first-and-only preventative therapy for CSA-AKI",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd4dd9d5-691b-4b41-856e-1ebe888dfe7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.04,
        "y": 0.36
      },
      "kind": "chart",
      "text": "Kaplan-Meier survival curve comparing treated patients vs historical controls",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f01139c2-eed3-4772-b6a1-6c4492683cc1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.65,
        "y": 0.4
      },
      "kind": "metric",
      "text": "60-80% of mod-to-severe CKD patients experience AKI post-CPB",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d17f95e-9c66-4a8f-98f7-53c441050dc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.1,
        "x": 0.55,
        "y": 0.4
      },
      "kind": "metric",
      "text": "1/4 patients develop AKI post-surgery",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ce146ec-0b2a-4019-b6d3-a68110ba21a5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "1. Jodele, Dandoy, Lane, et al... 2. Epidemiology data on file...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d544c4d9-0437-45cd-825a-b61b3b451c5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.55,
        "y": 0.65
      },
      "kind": "table",
      "text": "Market sizing for patients with CKD at risk of AKI: 30k US, 17k EU5, 7k Japan",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30ce767f-6d9e-46e2-8204-298337a3ded2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Ultomiris indication expansion will continue",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5d2644e-9bd4-490c-9be9-882669e9bbcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Direct-to-Phase III trials and potential blockbuster opportunities in HSCT-TMA, CSA-AKI",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b6b29e0-8ed9-4ebb-863d-75e6b2971336",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Big Idea Formula",
      "slug": "big-idea-formula",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "ad350c36-92b3-41aa-8540-369fd76335f7",
      "evidence": "Ultomiris potential to be first-and-only medicine for HSCT-TMA, and first-and-only preventative therapy for CSA-AKI",
      "confidence": 0.7
    },
    {
      "name": "Storytelling: the three headline reasons",
      "slug": "three-reasons",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "64eedb14-5942-4f37-9d4e-ebd74c307d35",
      "evidence": "Ultomiris indication expansion will continue, Ultomiris potential to be first-and-only medicine for HSCT-TMA, and first-and-only preventative therapy for CSA-AKI",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 10,
      "beatId": "d3c23a4e-d701-4880-ab73-2b10c287783d",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The document outlines AstraZeneca's approach to addressing rare diseases, including its pipeline of medicines and focus on complement inhibition",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 10,
      "name": "Mece Breakdown",
      "slug": "40-mece-breakdown",
      "bestFor": "Problem structuring, ensuring completeness, strategic analysis",
      "matchId": "c4172741-e04e-4f5c-8db1-c8617215367b",
      "evidence": "The document provides a breakdown of the company's pipeline and how it addresses different medical needs",
      "position": 1,
      "objective": "How AstraZeneca's pipeline addresses high unmet medical needs",
      "structure": "The Whole -> Category A (distinct) -> Category B (distinct) -> Category C (distinct) -> Complete Coverage",
      "confidence": 0.6,
      "description": "Divide a complex topic into mutually exclusive, collectively exhaustive categories"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}